Please login to the form below

Not currently logged in
Email:
Password:

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light
EU flag

The European Commission (EC) has approved Takeda's Entyvio (vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance (empagliflozin), which adds to the growing list of treatments for type 2 diabetes.

The approvals cover the European Union and come two months after scientific advisers at the European Medicines Agency (EMA) backed both products, and the same week that Entyvio was approved by the US FDA.

As per this recommendation, Entyvio is approved to treat patients with ulcerative colitis and Crohn's disease who cannot tolerate or who respond poorly to conventional therapy or a tumour necrosis factor (TNF) antagonist such as J&J's Remicade (infliximab)

Both conditions are types of inflammatory bowel disease and are thought to affect more than two million people in Europe, potentially offering a large market to Takeda despite the limited approval.

Entyvio - a humanised monoclonal antibody - marks Takeda's first step into inflammatory bowel disease, and has been cited by the company as a key part of its growth plans.

Data from late-stage trials back these ambitions, demonstrating the drug's effectiveness in improving remission rates.

Meanwhile, Boehringer and Lilly also celebrated obtaining EU marketing authorisation for their diabetes treatment Jardiance – the latest in a new class of drugs called SGLT-2 inhibitors to win approval.

These treatments work independently of insulin by blocking the re-absorption of glucose into the bloodstream, causing it to be removed via the urine. 

SGLT-2 inhibitors already on the market in Europe include Johnson & Johnson's Invokana (canagliflozin) and AstraZeneca's Forxiga (dapagliflozin).

Both these products are also available as combination treatments with metformin in versions called Vokanamet (Invokana and metformin) and Xigduo (Forxiga and metformin).

The EC approval gives Boehringer and Lilly and a chance to catch up on their rivals and a combination of Jardiance and metformin is also in the works.

Article by
Thomas Meek

28th May 2014

From: Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....